A pharmacokinetics study to evaluate drug-drug interactions between fipaxalparant and concomitant medications in healthy participants
{{output}}
Fipaxalparant, a small molecule and negative allosteric modulator of lysophosphatidic acid receptor 1, is being evaluated in phase 2 clinical trials of idiopathic pulmonary fibrosis (IPF) and diffuse cutaneous systemic sclerosis. This phase 1, open-label, cros... ...
